Saved in:
Bibliographic Details
Main Authors: Vu, Quoc Dang, Fong, Caroline, Gordon, Anderley, Lund, Tom, Silveira, Tatiany L, Rodrigues, Daniel, von Loga, Katharina, Raza, Shan E Ahmed, Cunningham, David, Rajpoot, Nasir
Format: Preprint
Published: 2024
Subjects:
Online Access:https://arxiv.org/abs/2402.19296
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1866914697023848448
author Vu, Quoc Dang
Fong, Caroline
Gordon, Anderley
Lund, Tom
Silveira, Tatiany L
Rodrigues, Daniel
von Loga, Katharina
Raza, Shan E Ahmed
Cunningham, David
Rajpoot, Nasir
author_facet Vu, Quoc Dang
Fong, Caroline
Gordon, Anderley
Lund, Tom
Silveira, Tatiany L
Rodrigues, Daniel
von Loga, Katharina
Raza, Shan E Ahmed
Cunningham, David
Rajpoot, Nasir
contents Gastric and oesophageal (OG) cancers are the leading causes of cancer mortality worldwide. In OG cancers, recent studies have showed that PDL1 immune checkpoint inhibitors (ICI) in combination with chemotherapy improves patient survival. However, our understanding of the tumour immune microenvironment in OG cancers remains limited. In this study, we interrogate multiplex immunofluorescence (mIF) images taken from patients with advanced Oesophagogastric Adenocarcinoma (OGA) who received first-line fluoropyrimidine and platinum-based chemotherapy in the PLATFORM trial (NCT02678182) to predict the efficacy of the treatment and to explore the biological basis of patients responding to maintenance durvalumab (PDL1 inhibitor). Our proposed Artificial Intelligence (AI) based marker successfully identified responder from non-responder (p < 0.05) as well as those who could potentially benefit from ICI with statistical significance (p < 0.05) for both progression free and overall survival. Our findings suggest that T cells that express FOXP3 seem to heavily influence the patient treatment response and survival outcome. We also observed that higher levels of CD8+PD1+ cells are consistently linked to poor prognosis for both OS and PFS, regardless of ICI.
format Preprint
id arxiv_https___arxiv_org_abs_2402_19296
institution arXiv
publishDate 2024
record_format arxiv
spellingShingle An AI based Digital Score of Tumour-Immune Microenvironment Predicts Benefit to Maintenance Immunotherapy in Advanced Oesophagogastric Adenocarcinoma
Vu, Quoc Dang
Fong, Caroline
Gordon, Anderley
Lund, Tom
Silveira, Tatiany L
Rodrigues, Daniel
von Loga, Katharina
Raza, Shan E Ahmed
Cunningham, David
Rajpoot, Nasir
Computer Vision and Pattern Recognition
Machine Learning
Gastric and oesophageal (OG) cancers are the leading causes of cancer mortality worldwide. In OG cancers, recent studies have showed that PDL1 immune checkpoint inhibitors (ICI) in combination with chemotherapy improves patient survival. However, our understanding of the tumour immune microenvironment in OG cancers remains limited. In this study, we interrogate multiplex immunofluorescence (mIF) images taken from patients with advanced Oesophagogastric Adenocarcinoma (OGA) who received first-line fluoropyrimidine and platinum-based chemotherapy in the PLATFORM trial (NCT02678182) to predict the efficacy of the treatment and to explore the biological basis of patients responding to maintenance durvalumab (PDL1 inhibitor). Our proposed Artificial Intelligence (AI) based marker successfully identified responder from non-responder (p < 0.05) as well as those who could potentially benefit from ICI with statistical significance (p < 0.05) for both progression free and overall survival. Our findings suggest that T cells that express FOXP3 seem to heavily influence the patient treatment response and survival outcome. We also observed that higher levels of CD8+PD1+ cells are consistently linked to poor prognosis for both OS and PFS, regardless of ICI.
title An AI based Digital Score of Tumour-Immune Microenvironment Predicts Benefit to Maintenance Immunotherapy in Advanced Oesophagogastric Adenocarcinoma
topic Computer Vision and Pattern Recognition
Machine Learning
url https://arxiv.org/abs/2402.19296